JP2006524243A5 - - Google Patents

Download PDF

Info

Publication number
JP2006524243A5
JP2006524243A5 JP2006509825A JP2006509825A JP2006524243A5 JP 2006524243 A5 JP2006524243 A5 JP 2006524243A5 JP 2006509825 A JP2006509825 A JP 2006509825A JP 2006509825 A JP2006509825 A JP 2006509825A JP 2006524243 A5 JP2006524243 A5 JP 2006524243A5
Authority
JP
Japan
Prior art keywords
use according
animal
syndrome
cognitive
training
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006509825A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006524243A (ja
JP4833834B2 (ja
Filing date
Publication date
Priority claimed from US10/410,508 external-priority patent/US20040224316A1/en
Application filed filed Critical
Publication of JP2006524243A publication Critical patent/JP2006524243A/ja
Publication of JP2006524243A5 publication Critical patent/JP2006524243A5/ja
Application granted granted Critical
Publication of JP4833834B2 publication Critical patent/JP4833834B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006509825A 2003-04-08 2004-04-08 増強認知訓練 Expired - Fee Related JP4833834B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/410,508 US20040224316A1 (en) 2000-08-10 2003-04-08 Augmented cognitive training
US10/410,508 2003-04-08
PCT/US2004/010876 WO2004091609A2 (en) 2001-08-10 2004-04-08 Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit

Publications (3)

Publication Number Publication Date
JP2006524243A JP2006524243A (ja) 2006-10-26
JP2006524243A5 true JP2006524243A5 (cg-RX-API-DMAC10.html) 2011-03-24
JP4833834B2 JP4833834B2 (ja) 2011-12-07

Family

ID=37416211

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006509825A Expired - Fee Related JP4833834B2 (ja) 2003-04-08 2004-04-08 増強認知訓練

Country Status (7)

Country Link
US (2) US20040224316A1 (cg-RX-API-DMAC10.html)
EP (4) EP2340831B1 (cg-RX-API-DMAC10.html)
JP (1) JP4833834B2 (cg-RX-API-DMAC10.html)
AT (1) ATE556707T1 (cg-RX-API-DMAC10.html)
CA (1) CA2521839C (cg-RX-API-DMAC10.html)
ES (3) ES2403283T3 (cg-RX-API-DMAC10.html)
WO (1) WO2004091609A2 (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8153646B2 (en) 2000-08-10 2012-04-10 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US7947731B2 (en) 2000-08-10 2011-05-24 Cold Spring Harbor Laboratory Augmented cognitive training
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
US9931318B2 (en) 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US8975216B2 (en) * 2006-03-30 2015-03-10 Pacific Biosciences Of California Articles having localized molecules disposed thereon and methods of producing same
EP2377533A3 (en) * 2006-05-19 2012-02-22 Helicon Therapeutics, Inc. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
GB0722769D0 (en) * 2007-11-21 2008-01-02 Biolipox Ab New compounds
AR065709A1 (es) * 2007-03-12 2009-06-24 Biolipox Ab Piperidinonas y composiciones farmaceuticas que las contienen usadas para el tratamiento de la inflamacion. procesos de obtencion.
AU2008254907A1 (en) * 2007-05-15 2008-11-27 Helicon Therapeutics, Inc. Methods of identifying genes involved in memory formation using small interfering RNA(siRNA)
US7968524B2 (en) * 2007-05-15 2011-06-28 Helicon Therapeutics, Inc. Methods of enhancing long term memory formation by inhibition of Gpr12
JP5049713B2 (ja) * 2007-09-14 2012-10-17 株式会社コナミデジタルエンタテインメント ゲームシステム並びにこれを構成するゲーム装置及び課題報知装置
BRPI0916228A2 (pt) * 2008-07-18 2015-11-03 Dart Neuroscience Llc métodos e sistemas para avaliação de agentes de memória
WO2011114103A1 (en) 2010-03-18 2011-09-22 Biolipox Ab Pyrimidinones for use as medicaments
US20150050626A1 (en) * 2013-03-15 2015-02-19 Dart Neuroscience, Llc Systems, Methods, and Software for Improving Cognitive and Motor Abilities
US20170119775A1 (en) * 2014-03-28 2017-05-04 Algiax Pharmaceuticals Gmbh Treatment of cognitive disorders
JP2017141222A (ja) * 2016-02-09 2017-08-17 国立大学法人帯広畜産大学 パーキンソン病に併発した認知障害の治療剤及びそのスクリーニング方法
CN116963773B (zh) 2021-01-21 2026-05-08 浙江养生堂天然药物研究所有限公司 治疗肿瘤的组合物及方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5479508A (en) * 1991-05-22 1995-12-26 Zenith Electronics Corp. Method of operating a pay per view television system
US5547979A (en) * 1992-03-30 1996-08-20 Smithkline Beecham TNF inhibition
FI944549L (fi) 1992-04-02 1994-11-30 Smithkline Beecham Corp Allergisten ja tulehdussairauksien hoidossa käyttökelpoiset yhdisteet
AU678158B2 (en) 1992-04-10 1997-05-22 Fox Chase Cancer Center Transcription control element for increasing gene expression in myoblasts
WO1996006843A1 (en) * 1994-08-29 1996-03-07 Yamanouchi Pharmaceutical Co., Ltd. Novel naphthyridine derivative and medicinal composition thereof
US5619249A (en) * 1994-09-14 1997-04-08 Time Warner Entertainment Company, L.P. Telecasting service for providing video programs on demand with an interactive interface for facilitating viewer selection of video programs
EP0781335A1 (en) 1994-10-07 1997-07-02 Cold Spring Harbor Laboratory Cloning and characterizing of genes associated with long-term memory
US5929223A (en) * 1994-10-07 1999-07-27 Cold Spring Harbor Laboratory Cloning and characterizing of genes associated with long-term memory
US5652749A (en) * 1995-02-03 1997-07-29 International Business Machines Corporation Apparatus and method for segmentation and time synchronization of the transmission of a multiple program multimedia data stream
US5793410A (en) * 1995-05-26 1998-08-11 Hyundai Electronics America Video pedestal network
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
EP0936923B1 (en) * 1996-11-15 2003-12-17 Kennedy Institute Of Rheumatology SUPPRESSION OF TNFalpha AND IL-12 IN THERAPY
SK283270B6 (sk) * 1997-01-15 2003-04-01 Altana Pharma Ag Ftalazinóny, farmaceutické prostriedky s ich obsahom a ich použitie
WO2000014083A1 (en) 1998-09-09 2000-03-16 Inflazyme Pharmaceuticals Ltd. SUBSTITUTED η-PHENYL-Δ-LACTONES AND ANALOGS THEREOF AND USES RELATED THERETO
IT1303272B1 (it) 1998-10-29 2000-11-06 Zambon Spa Derivati triciclici inibitori della fosfodiesterasi 4
WO2000050402A1 (en) 1999-02-25 2000-08-31 Merck Frosst Canada & Co. Pde iv inhibiting compounds, compositions and methods of treatment
US6436965B1 (en) 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
CA2402384A1 (en) 2000-03-16 2001-09-20 Inflazyme Pharmaceuticals Ltd. Benzylated pde4 inhibitors
US7947731B2 (en) * 2000-08-10 2011-05-24 Cold Spring Harbor Laboratory Augmented cognitive training
DK1540335T3 (da) * 2002-08-19 2010-07-26 Helicon Therapeutics Inc Screeningsfremgangsmåder til kognitive forstækere

Similar Documents

Publication Publication Date Title
Beaudin et al. Impact of obstructive sleep apnoea and intermittent hypoxia on cardiovascular and cerebrovascular regulation
Kemeny et al. Emotions, the neuroendocrine and immune systems, and health
JP2019031502A5 (cg-RX-API-DMAC10.html)
JP2018520189A5 (cg-RX-API-DMAC10.html)
EA200700427A1 (ru) Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
EP3442581A1 (en) Use of cannabidivarin in the treatment of autism spectrum disorder, associated disorders and schizophrenia
WO2017190044A8 (en) Methods for detecting and treating pain using brain activity
DE60333857D1 (de) Oxytocin zur Behandlung von Autismus und Asperger-Syndrom
Guercio et al. Improving cognitive training for schizophrenia using neuroplasticity enhancers: Lessons from decades of basic and clinical research
DE60326548D1 (de) Verfahren zur verhütung oder behandlung von herzarrhythmie
DE602005025347D1 (de) Oligoribonukleotide und verfahren zu deren anwendung bei der behandlung von fibrotischen leiden und anderen krankheiten
JP2009537568A5 (cg-RX-API-DMAC10.html)
JP5517925B2 (ja) パーキンソン病治療薬
JP5517926B2 (ja) パーキンソン病治療薬
Tellez et al. Autoradiographic study of serotonin transporter during memory formation
ATE429216T1 (de) Alpha 2b oder 2b/2c adrenozeptor-agonisten zur behandlung von morbus alzheimer und morbus parkinson
JP2025509709A (ja) 発症前神経変性状態の調査診断としてのセルフリーｄｎａからの神経メチル化シグネチャー
RU2005114505A (ru) Применение (2-имидазолин-2-иламино) хиноксалинов для лечения деменции и болезни паркинсона
ATE432070T1 (de) Herabgesetzte dosis von tolterodin zur behandlung von harnwegserkrankungen
RU2006146326A (ru) Способ лечения хронического вирусного гепатита с
Doe et al. Behavioral despair during a water maze learning task in mice
Mattson Exercise and the brain: a slap on the HAND
Melloni et al. Safinamide and glutamate release: new insights
JP2012090626A (ja) 疲労の評価方法
Orihuela-Flores et al. Naltrexone in adults with intellectual disability improves compulsive and dissocial disorders: A case report